Sign in
Taking people in United StatesNo phase

Collects samples from people with several cancers to study a blood test

Collects blood and tissue samples from adults with solid tumors to test a monitoring method.

Key facts

Who runs it
Natera, Inc.
Where
Austin, United StatesSee the site
Trial code
Registry title
Sample Collection for Ongoing Research and Product Evaluation Study
Status
Recruiting
People taking part
9,600 people, planned
Started
21 Jul 2025
Expected to end
Jan 2035
Type of study
Observational
Record updated
15 January 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with a new solid tumor that has not been treated yet, such as breast, lung, bladder, rectal, pancreatic, ovarian, prostate, liver, womb, head and neck cancer, or melanoma. Blood and tumor samples are collected for research.

Age
18 years or older
Sex
Women and men
Disease stage
Untreated primary solid cancer of one of the listed types. Pancreatic, womb, bladder or ovarian cancer may also be suspected from imaging. Performance status ECOG ≤ 2.
Earlier treatment
No treatment for the cancer yet, and no treatment given after surgery. No cancer history or treatment within the past year. No earlier ctDNA test for leftover disease, except genomic profiling to choose treatment.

Main reasons for not taking part

  • Pregnant or breastfeeding
  • Another active cancer, or any cancer treated in the past year (skin squamous or basal cell cancer removed by surgery is allowed)
  • Already started drug treatment after surgery
  • History of bone marrow or organ transplant
  • Serious medical conditions that could affect taking part

The registry criteria, word for word

Show all 14 criteriaShow less

Who can take part

  • 18 years of age or older
  • Any patient that has an untreated primary solid malignancy within the following cohorts:; Breast cancer; Lung cancer; Muscle invasive bladder cancer; Rectal cancer; Pancreatic cancer; Ovarian cancer; Gastroesophageal cancer; Prostate cancer; Melanoma; Hepatic/liver cancer; Uterine/endometrial cancer; Head and neck Cancer
  • The participant has a suspected primary malignancy of pancreatic, endometrial, bladder, or ovarian cancer based on imaging
  • Eastern Cooperative Oncology Group performance status ≤ 2
  • Able to tolerate venipuncture for research blood draw(s)
  • Consent to provide residual tumor tissue for research
  • Willing and able to comply with the study requirements
  • Signed informed consent(s) must be obtained prior to participation in the study

Who cannot take part

  • Prior history and treatment for any cancer within the past year or has another active cancer, with the exception of participants who have undergone surgical removal of skin squamous cell or basal cell cancers
  • At time of enrollment, has undergone or plans to undergo any ctDNA testing to assess molecular residual disease, with the exception of comprehensive genomic profiling for therapeutic selection
  • History of bone marrow or organ transplant
  • Serious medical conditions that may adversely affect ability to participate in the study
  • Pregnant or breastfeeding
  • Has initiated postoperative systemic treatment

Where in United States

  • Natera, Inc.Austin, United StatesContact: Jamie McKenzie, MDTaking people

About the trial

What the trial wants to find out

The SCORE study is a prospective, multi-site clinical trial designed to collect blood and tissue samples, along with relevant clinical data, from participants diagnosed with various solid tumors. The collected specimens and information will be used to evaluate the clinical performance of Natera's molecular residual disease (MRD) testing across multiple cancer types. The study aims to assess the ability of Natera's assays to detect circulating tumor DNA (ctDNA) as a marker for disease recurrence and treatment response.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Sample Collection for Ongoing Research and Product Evaluation (SCORE) Study
Plain-language title
Collects samples from people with several cancers to study a blood testGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 13 November 2026.
Record updated
15 January 2026